This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Clock Drawing Test | |
|---|---|
| Name | Clock Drawing Test |
| Purpose | Brief cognitive screening for visuospatial and executive function |
| Administered | Pen-and-paper or digital tablet |
| Time | 1–5 minutes |
| Scored | Multiple structured scoring systems |
| Synonyms | CDT |
Clock Drawing Test
The Clock Drawing Test is a brief cognitive screening tool used to assess visuospatial ability, executive function, and praxis in clinical and research settings. It is commonly employed alongside instruments such as the Mini-Mental State Examination, the Montreal Cognitive Assessment, and the Addenbrooke's Cognitive Examination to aid detection of cognitive impairment associated with conditions like Alzheimer's disease, Parkinson's disease, and vascular dementia.
The test typically asks a subject to draw a clock face, place the numbers, and set the hands to a specified time (for example, "10 past 11"). Its demands engage graphomotor skills, number sequencing, spatial organization, and planning, implicating neural systems in the frontal lobe, parietal lobe, and subcortical structures such as the basal ganglia. Performance is sensitive to deficits observed after events like the middle cerebral artery infarction or in progressive disorders linked to the apolipoprotein E genotype. The CDT is used worldwide in clinical settings including Johns Hopkins Hospital, Mayo Clinic, and community screening programs in nations such as United Kingdom, United States, and Canada.
Administration is simple: paper and pencil or a digital tablet are provided with standard instructions; variants ask for drawing from command or copying a model. Scoring ranges from very brief binary checks to multi-item instruments like the Shulman score, although original procedures were developed in outpatient clinics similar to those at Bellevue Hospital, Massachusetts General Hospital, and Stanford Hospital. Examiners trained in neuropsychology or geriatrics—practitioners affiliated with institutions such as American Psychological Association, Royal College of Psychiatrists, and Alzheimer's Association—use standardized sheets to rate features including number placement, hand length, and contour integrity.
Clinically, the CDT assists in screening for dementias including Alzheimer's disease, Lewy body dementia, and frontotemporal dementia, and in assessing impairment after events like stroke or traumatic brain injury. It complements neuroimaging findings from magnetic resonance imaging and computed tomography and neurophysiological data from centers such as National Institutes of Health research programs. The test contributes to multidisciplinary evaluations involving neurologists from institutions like Mayo Clinic and geriatric teams at Mount Sinai Health System when making decisions about capacity, driving, or referral for in-depth neuropsychological assessment.
Multiple variants exist: command versus copy conditions, free-drawing, and timed or digital capture on devices produced by companies collaborating with research centers such as Massachusetts Institute of Technology and University of California, San Francisco. Several scoring systems are widely cited including the Shulman score, the Watson score, and multi-domain systems used in longitudinal cohorts like the Framingham Heart Study and the Rotterdam Study. Computerized scoring algorithms have been developed in partnership with researchers at Carnegie Mellon University and University of Pennsylvania to quantify features such as inter-digit spacing and pen lift frequency.
Interpretation requires clinical context: factors such as visual acuity deficits treated at Bascom Palmer Eye Institute, motor impairments from Parkinson's disease therapies, cultural differences noted in cross-national studies involving World Health Organization sites, and educational background influence performance. Sensitivity and specificity vary by population and scoring method; cutoffs established in cohort studies like Alzheimer's Disease Neuroimaging Initiative should be applied cautiously. Language barriers, illiteracy, and conditions treated at facilities such as Médecins Sans Frontières settings limit generalizability.
The CDT emerged from bedside cognitive screening traditions in hospitals like Bellevue Hospital and clinics influenced by early neuropsychologists connected to Harvard Medical School and UCL. Pioneering work in the 20th century paralleled advances in neuroimaging at institutions such as Johns Hopkins Hospital and research networks including National Institute of Neurological Disorders and Stroke. Subsequent refinements incorporated scoring approaches developed by clinicians associated with University College London and University of Toronto.
Research evaluates reliability, validity, and predictive utility in cohorts from studies such as the Framingham Heart Study, Alzheimer's Disease Neuroimaging Initiative, and population samples recruited through centers like Karolinska Institutet and University of Cambridge. Psychometric properties vary: inter-rater reliability is generally acceptable when raters are trained at programs sponsored by organizations like the American Academy of Neurology, while construct validity is supported by correlations with established measures including the Mini-Mental State Examination and performance on neuroimaging markers from PET imaging studies. Ongoing research at universities such as Columbia University, University of California, Los Angeles, and University of Oxford explores machine-learning scoring, cross-cultural norms, and predictive value for conversion from mild cognitive impairment to Alzheimer's disease.
Category:Cognitive tests